(Total Views: 596)
Posted On: 11/09/2021 7:07:56 AM
Post# of 153903
Crazyjogger,
Sacituzumab is a really good drug, targeting the Trop-2 protein and directing SN-38 (a topoisomerase inhibitor) to cancer cells, preventing DNA unwinding and cancer replication.
Leronlimab appears to block tumor metastasis (angiogenesis and invasion) as well as reversing the comfy tumor micro environment allowing the immune system "access" to the cancer cells (Dr. Patterson's descriptions of the mechanism remain among the most comprehensible to me. His scientific acumen remains, IMO, unimpeachable).
I would love to see a Trodelvy (sacituzumab and SN-38) trial with leronlimab. These seem to have a great likelihood of working well together. As Ohm noted, leronlimab is likely to supplant checkpoint inhibitors (Keytruda).
Kabonk, Ohm and others can certainly expound on this, but both IMO are valuable for TNBC
Sacituzumab is a really good drug, targeting the Trop-2 protein and directing SN-38 (a topoisomerase inhibitor) to cancer cells, preventing DNA unwinding and cancer replication.
Leronlimab appears to block tumor metastasis (angiogenesis and invasion) as well as reversing the comfy tumor micro environment allowing the immune system "access" to the cancer cells (Dr. Patterson's descriptions of the mechanism remain among the most comprehensible to me. His scientific acumen remains, IMO, unimpeachable).
I would love to see a Trodelvy (sacituzumab and SN-38) trial with leronlimab. These seem to have a great likelihood of working well together. As Ohm noted, leronlimab is likely to supplant checkpoint inhibitors (Keytruda).
Kabonk, Ohm and others can certainly expound on this, but both IMO are valuable for TNBC
(11)
(0)
